Ambu A/S (OTCMKTS:AMBBY) Downgraded to “Hold” Rating by UBS Group

Ambu A/S (OTCMKTS:AMBBY) was downgraded by research analysts at UBS Group from a “strong-buy” rating to a “hold” rating in a research note issued on Tuesday, Zacks reports.

Ambu A/S Stock Up 0.5%

Ambu A/S stock opened at $10.25 on Tuesday. The stock has a 50 day moving average of $10.73 and a two-hundred day moving average of $10.46. Ambu A/S has a twelve month low of $8.54 and a twelve month high of $16.78. The stock has a market capitalization of $2.41 billion, a price-to-earnings ratio of 34.17 and a beta of 0.93. The company has a current ratio of 2.92, a quick ratio of 1.73 and a debt-to-equity ratio of 0.08.

Ambu A/S (OTCMKTS:AMBBY) last released its earnings results on Tuesday, August 25th. The company reported $0.09 earnings per share (EPS) for the quarter. Ambu A/S had a return on equity of 8.56% and a net margin of 8.18%.The business had revenue of $255.12 million for the quarter.

Ambu A/S Company Profile

Ambu A/S is a Danish medical technology company that develops, manufactures and markets single-use devices for hospitals and other healthcare providers. The company focuses on reducing the need to reprocess reusable equipment while supporting clinical procedures in areas such as endoscopy, anesthesia and patient monitoring.

Ambu’s product portfolio includes disposable endoscopes and related visualization systems, airway management products, anesthesia equipment and devices used for patient monitoring and diagnostics.